Best Life Sciences Companies in Wallonia, Belgium
The 108 best Life Sciences companies in Wallonia, Belgium in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Univercells.
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Wallonia
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Univercells Provider of biomanufacturing technology services for biopharma sector | $151M | 44 mo ago | 88 | Jose Castillo Co-Founder & CTO | WordPressZohoMySQL+25 | Top 50M | 74 patents Biomanufacturing platforms for cell culture, protein purification, and viral vaccine production | — |
| 2 | Miracor Medical Manufacturer of therapeutic medical devices for impaired cardiac function | $117M | 69 mo ago | 16 | — | — | — | 40 patents Mechanical circulatory support devices for heart assistance, e.g., ventricular assist systems. | — |
| 3 | Nyxoah Provider of a neurostimulation device for obstructive sleep apnea treatments | $89M | 6 mo ago | 11 | Robert Taub Founder & Executive Chairman | DrupalPHPUbuntu+18 | Top 10M | 258 patents Implantable neurostimulation devices for treating obstructive sleep apnea. | 1 partnership · 1 award |
| 4 | Novadip Developer of stem cell-based therapies for bone healing disorders and bone defects | $77M | 30 mo ago | 39 39 → 58 (+49%) · sector median +26% | — | WordPressMySQLPHP+16 | Top 50M | — | — |
| 5 | iSTAR Medical Developer of minimally-invasive glaucoma surgery (MIGS) implant | $61M | 81 mo ago | 28 28 → 38 (+36%) · sector median +26% | Michel Vanbrabant CEO | WordPressApple iCloud MailMicrosoft 365+17 | Top 50M | 59 patents Catheter-based delivery systems for spinal and orthopedic implants | — |
| 6 | Imcyse Developer of a portfolio of pharmaceuticals against multiple diseases | $57M | 64 mo ago | 48 | Denis Bedoret CEO | — | — | 216 patents Therapeutic peptide design for autoimmune disease treatment, e.g., diabetes and neuromyelitis optica | — |
| 7 | ATB Therapeutics Developer of mAb based therapy in oncology | $57M | 19 mo ago | 13 | Bertrand Magy Co-Founder & CEO | UbuntuAnimate.cssReact+10 | Top 50M | 30 patents Plant-produced antibody-toxin fusion immunotherapies targeting CD79b for cancer treatment | 2 job openings |
| 8 | CryoTherapeutics Developer of catheter technology for interventional cardiology to treat heart attacks | $48M | 26 mo ago | 1 | — | — | — | 6 patents Medical therapeutic cooling devices for distal perfusion and refrigerant control | — |
| 9 | OncoDNA Theranostic and genomic company for precision medicine in oncology | $45M | 31 mo ago | 37 37 → 46 (+24%) · sector median +26% | — | Cart FunctionalityWordPressApple iCloud Mail+38 | Top 5M | 35 patents Personalized cancer neoantigen vaccines and tumor sequencing for individualized immunotherapy | — |
| 10 | Cellaion Developer of therapies for the treatment of chronic liver diseases | $44M | 85 mo ago | 24 | Etienne Sokal CEO | — | — | 17 patents Isolation and manufacturing of allogeneic adult liver progenitor cells for therapeutic use. | — |
| 11 | Bioxodes Developer of novel peptide therapies for prevention of thrombosis | $43M | 6 mo ago | 7 | Marc Dechamps CEO | — | — | 40 patents Therapeutic peptides for treating brain inflammation and neurodegenerative disorders | 1 launch |
| 12 | Volition Developer of cancer diagnostic tests | $40M | 2 mo ago | 104 | Cameron Reynolds CEO | WordPressMySQLPHP+26 | Top 10M | — | 1 launch · 1 partnership |
| 13 | Uteron Pharma Developing products dedicated to female healthcare. | $31M | 170 mo ago | 13 | Stijn Van Rompay Founder | — | — | — | — |
| 14 | Amyl Therapeutics Developer of therapeutics for the treatment of amyloidosis | $28M | 31 mo ago | 4 | Florent Gros Chairman & Founder | WordPressPleskMySQL+16 | Top 50M | 12 patents Therapeutic peptides targeting amyloid interactions for disease-modifying protein therapeutics | — |
| 15 | IBA Provider of software and hardware solutions for life science and healthcare industry | $27M | 55 mo ago | 1,800 | Yves Jongen Founder & Chief Research Officer | DrupalPHPSalesforce+15 | Top 5M | 3 patents Monitoring and quality assurance of radiation therapy hardware performance | — |
| 16 | Epics therapeutics Developer of small molecules to treat cancer | $25M | 90 mo ago | 30 30 → 30 (+0%) · sector median +26% | Jean Combalbert Founder & CEO | — | — | 44 patents Small-molecule METTL3 methyltransferase inhibitors for oncology | — |
| 17 | NeuVasQ Biotechnologies Developer of therapeutics for acute neurological disorders and neurodegenerative diseases | $24M | 60 mo ago | 3 | Benoit Vanhollebeke Founder | — | — | 5 patents Engineered Wnt7 protein variants for therapeutic modulation of Wnt signaling pathways. | 2 launchs |
| 18 | The Akkermansia Company Developer of food supplements for human metabolic health issues | $22M | 30 mo ago | 5 | — | Amazon WebstoreCart FunctionalityShopify+16 | Top 5M | 34 patents Probiotic and nutraceutical formulations of Akkermansia muciniphila for weight/metabolic health. | 1 job opening |
| 19 | Syndesi Therapeutics Developer of small molecule for treating Alzheimer's disease | $21M | 87 mo ago | 1 | — | — | — | 14 patents Small‑molecule triazol derivatives for treating cognitive (neurodegenerative) disorders | — |
| 20 | Endo Tools Therapeutics Developer of an endoscopic catheter for gastroenterologists | $19M | 65 mo ago | 12 12 → 29 (+142%) · sector median +26% | Alexandre Chau CEO | WordPressApple iCloud MailMicrosoft 365+21 | Top 50M | 22 patents Minimally invasive surgical anchors and endoscopic tool support devices for tissue approximation | — |
| 21 | Bone Therapeutics Developer of cell therapy products for orthopedics and bone diseases | $18M | 50 mo ago | 20 20 → 16 (-20%) · sector median +26% | — | — | — | 195 patents Regenerative medicine biomaterials for stem‑cell differentiation and hyaluronic‑acid plasma formulations | — |
| 22 | Convert Pharmaceuticals Developer of small molecule based oncology therapeutics | $17M | 29 mo ago | 2 | Philippe Lambin Co-Founder | — | — | 6 patents Design and synthesis of novel prodrugs for enhanced pharmaceutical delivery and efficacy. | — |
| 23 | Synergia Medical Developer of an active implantable neurostimulator and contact-less patient monitoring system | $14M | 41 mo ago | 18 | Attila Borbath Co-Founder | — | — | 158 patents Implantable neurostimulation devices with optical sensing and power‑optimization technologies | — |
| 24 | Oncomfort Developer of a digital sedation device for managing pain and anxiety | $12M | 69 mo ago | 4 | Mario Huyghe Co-Founder & CEO | — | — | 39 patents Biomedical monitoring devices measuring consciousness, pain, and anxiety via skin-contact electrodes. | — |
| 25 | N-SIDE Provider of cloud and AI-based analytics for supply chain optimisation | $12M | 62 mo ago | 10 | Jacques Parlongue CEO | HubSpot CMS HubApple iCloud MailGoogle Workspace+22 | Top 10M | 8 patents Orthopedic implant molding and arthroplasty devices; supply‑chain optimization software; QR‑code social linking | 3 job openings · 1 award |
| 26 | Celyad Oncology Provider of regenerative therapies for the treatment of cancer and cardiovascular diseases | $10M | 54 mo ago | 32 | Michel Lussier Co-Founder & Chairman | WordPressMySQLPHP+26 | Top 10M | 17 patents Multiplexed inhibitory RNA scaffolds and NKG2D‑CAR cell therapies for cancer immunotherapy | — |
| 27 | Santero Therapeutics Developer of antibiotics to target resistant pathogens | $9M | 36 mo ago | 3 | Abel Pino Co-Founder | BackdropOdooPHP+10 | Top 50M | — | — |
| 28 | Diagenode Developer of portfolio of reagents and kits for epigenetics sequencing solutions | $8M | 81 mo ago | 99 99 → 125 (+26%) · sector median +26% | — | Cart FunctionalityPHPSalesforce+28 | Top 5M | 39 patents Patents concentrated in chemistry & materials | — |
| 29 | KiOmed Pharma Developer of bio-polymer chitosan based products | $7M | 120 mo ago | 20 20 → 48 (+140%) · sector median +26% | — | WordPressMySQLPHP+19 | Top 10M | 97 patents Modified anionic chitosan biopolymers for pharmaceutical drug delivery and formulation. | 1 launch · 1 partnership |
| 30 | DeuterOncology Developer of therapeutics for lung cancer | $6M | 41 mo ago | 4 | Timothy Perera Founder & CEO | — | — | — | — |
| 31 | Apaxen Developer of small molecules for treating pulmonary diseases | $4M | 81 mo ago | 4 | Bart Wuurman CEO | — | — | 2 patents Patents concentrated in health & consumer products | — |
| 32 | 3D-Side Provider of cloud-based 3D printing solutions to develop medical models and surgical guides | $3M | 47 mo ago | 17 17 → 39 (+129%) · sector median +26% | — | — | — | 8 patents Patents concentrated in health & consumer products | — |
| 33 | EsoBiotec Developer of in vivo adoptive cell therapies for cancer and autoimmune diseases. | $2M | 30 mo ago | 8 | — | WordPressMySQLPHP+12 | Top 10M | 9 patents Production platforms for viral vectors and engineered producer cell lines | — |
| 34 | Delphi Genetics Provider of research services in molecular biology, protein engineering, and antibody development | $1M | 119 mo ago | 85 | — | — | — | 26 patents Engineered bacterial hosts and modified bacteriophages for recombinant protein/biomolecule production | — |
| 35 | Cell Matters CDMO focused on manufacturing of cell therapy products | $872K | 100 mo ago | 6 | Delphine Connan Co-Founder | — | — | 10 patents Formulating cryopreservation solutions for preserving biological materials | — |
| 36 | SynAbs Developer of monoclonal antibody platform against poor immunogenic compounds | $632K | 42 mo ago | 8 | Yannick Nizet Co-Founder & CSO | JimdoAnimate.cssMustache+11 | Top 50M | 2 patents Therapeutic anti‑CCR8 antibodies for immunomodulation and disease treatment | — |
| 37 | StratiCELL Integrated solution provider for in vitro testing of skin care and dermatology products | $440K | 68 mo ago | 11 | Michel Salmon CEO | — | — | — | — |
| 38 | Progenus Provider of DNA analysis services and diagnostic kits | $395K | 29 mo ago | 14 14 → 14 (+0%) · sector median +26% | Robert Renaville Co-Founder & CEO | — | — | — | 3 launchs |
| 39 | Targetome Developing ADC (antibody-drug conjugates) for the treatment of cancer such as pancreatic cancer. | $393K | 123 mo ago | — | Christophe Van Huffel ex-CEO | — | — | — | — |
| 40 | DNAVision Provider of a wide range of genomic services to the pharmaceutical, food, and biotechnology industries | $294K | 88 mo ago | 5 | Laurent Alexandre CEO | — | — | — | — |
| 41 | Nuviant Medical Implantable neurostimulation systems for chronic diseases | $143K | 126 mo ago | 11 | — | — | — | — | — |
| 42 | DNAlytics Provider of data-driven personalized medicine from R&D to market access | $110K | 128 mo ago | 7 | Thibault Helleputte Founder & CEO | — | — | — | 2 launchs |
Top 12 Life Sciences companies in Wallonia
#1
Public · Gembloux, Wallonia · founded 1995 · 104 employees$40Mraised▾
Developer of cancer diagnostic tests. The Nu-Q is used for early cancer diagnostics by detecting nucleosome markers of cancer and early-stage cells in the blood. It has also developed vet cancer screening tests.
- Mar 2026Post IPO$2.3M
- May 2025Post IPO$22.6M
- Mar 2024Post IPO$100K
- Dec 2023Post IPO$5.4M
#2
Public · Mont Saint Guibert, Wallonia · founded 2009 · 11 employees$88.7Mraised▾
Provider of a neurostimulation device for obstructive sleep apnea treatments. The company's product BLAST-OSA (BiLAteral Hypoglossal Nerve Stimulation for Treatment of Obstructive Sleep Apnea) is used for treating sleep apnea and calculating ODI (Oxygen Desaturation Index) and AHI (Apnea-Hypopnea Index). Its system consists of an implant and disposable patch, which stimulate the nerves of the tongue to make it move, preventing airway obstruction.
- Dec 2025Post IPO$26.4M
- Apr 2023Post IPO$3M
- Feb 2020Series C$27.3M
- Nov 2018Series B$17M
#3
Series A · Marche en Famenne, Wallonia · founded 2013 · 7 employees$42.6Mraised▾
Developer of novel peptide therapies for prevention of thrombosis. The Company’s lead programme, Ir-CPI, is being developed for the prevention of thrombosis in a range of applications including cardiopulmonary bypass grafting and percutaneous coronary intervention.
- Dec 2025Series A$6.4M
- Feb 2025Series A$2.8M
- Nov 2023Series A$13.1M
#4
Series A · Marche en Famenne, Wallonia · founded 2017 · 13 employees$56.9Mraised▾
ATB Therapeutics is developing mAb-based therapy in oncology. The company aims to generate a pipeline of assets for hematological and solid cancers. The company is currently entering in preclinical stage.
- Nov 2024Series A$56.9M
#5
Series B · Mont Saint Guibert, Wallonia · founded 2013 · 39 employees$77Mraised▾
Developer of stem cell-based therapies for bone healing disorders and bone defects. The company has developed regenerative therapeutics which include NVD-X3 for hard tissue reconstruction and NVD-X2 for soft tissue reconstruction. The m3 platform technology creost is a 3D osteogenic structure from autologous adipose-derived stem cells which reconstruct critical size bone defects without the use of any scaffold.
- Dec 2023Venture Debt$19.7M
- Nov 2022Grant (prize money)$15.8M
- Nov 2022Series B$23.7M
- Oct 2021Series B$22M
#6
Series B · Loncin, Wallonia · founded 2009 · 1 employees$47.5Mraised▾
Developer of catheter technology for interventional cardiology to treat heart attacks. The company focuses on creating a device for use by interventional cardiologists. This technology aims to treat areas of coronary arteries that are prone to causing heart attacks. The goal is to promote arterial repair without the need for a stent.
- Apr 2024Series B$10.8M
- Feb 2022Series B$14M
- Jun 2019Series B$8M
- Jul 2016Series B$5.8M
#7
Series D · Charleroi, Wallonia · founded 2013 · 88 employees$150.6Mraised▾
Univercells technologies have developed instrument systems for the production of antibodies, proteins, and vaccines. The company's proprietary technology includes scale-x bioreactor and nevoline platform. Scale-x bioreactor provides upstream processing of viral products which can help to deliver viral vaccines and gene therapies.
- Oct 2022Series D$43.3M
- Dec 2020Series C$85.2M
- Feb 2020Series C—
- Oct 2019Conventional Debt$21.9M
#8
Series C · Charleroi, Wallonia · founded 2012 · 37 employees$44.5Mraised▾
Theranostic and genomic company for precision medicine in oncology. The company's biomarker tests include OncoDEEP for precision medicine, OncoSELECT is a liquid biopsy solution for monitoring and therapeutics, and OncoFOLLOW is to monitor the progression of the tumor. Also has NGS interpretation platform OncoKDM for clinical information and biomarker test platform OncoSHARE.
#9
Series A · Liege, Wallonia · founded 2020 · 4 employees$27.7Mraised▾
Developer of therapeutics for the treatment of amyloidosis. The company has a technology platform named ClariTY for developing therapeutic candidates that target multiple misfolded proteins in both progressive peripheral and neurodegenerative rare diseases.
- Nov 2023Series A$5.4M
- Jun 2021Series A$22.3M
#10
Acquired · Mont-Saint-Guibert, Wallonia · founded 2016 · 5 employees$22.1Mraised▾
Developer of food supplements for human metabolic health issues. The company's products are formulated with pasteurised Akkermansia that contains chamomile extract, riboflavin and folic acid and to support a healthier gut and control blood glucose levels.
- Dec 2023Venture Debt$21.9M
- Jan 2023Grant (prize money)$234.6K
#11
Series A · Liege, Wallonia · founded 2017 · 2 employees$16.7Mraised▾
Convert Pharmaceuticals is involved in the development of small molecule-based oncology therapeutics. The company develops hypoxia-activated cytotoxic small molecules. These therapeutics will act complementary to existing therapies in treatment-resistant areas of solid tumors while maintaining a favorable toxicity profile. The lead drug candidate, CP-506, is a hypoxia-activated prodrug.
- Jan 2024Grant (prize money)$2.7M
- 2023Grant (prize money)$4.5M
- Feb 2018Series A$16.7M
#12
Series E · Awans, Wallonia · founded 2008 · 16 employees$116.5Mraised▾
Miracor Medical is the manufacturer of a therapeutic medical device for patients with impaired cardiac function. It has developed CE-marked PiCSO (Pressure-controlled Intermittent Coronary Sinus Occlusion) impulse system consisting of a driving console and associated catheters for improving outcomes for severe heart attack patients. The PICSO Impulse system increases blood flow to the affected heart tissue and improving the overall heart function after a heart attack. The company is conducting post-market clinical trials of the PiCSO Impulse System.
- Sep 2020Series E$28.7M
- Jan 2020Grant (prize money)$54.7K
- Sep 2018Series D$34.8M
- Jan 2018Series D$30.1M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.